Table 6.

Laboratory Monitoring and Immunization for the HIV-Exposed Infant (Birth to 6 Months of Age)*

Age
Birth2 wk4 wk6 wk2 mo3 mo4 mo5 mo6 mo
Assess risk of other diseasesx
Continuation of ACTG-076 regimenxxxx
CBC and differential leukocyte counts§xxxxxx
PCR for HIV DNA and/or viral culture for HIVxxx
T-cell profilexx
Quantitative immunoglobulinsx
Initiate prophylaxis for Pneumocystis carinii pneumoniax
Immunizations
 Hepatitis Bxxx
 Diphtheria-pertussis-tetanusxxx
Haemophilus influenzae#xxx
 Polio vaccine (IPV)xx
  • * ACTG-076 indicates AIDS (Acquired Immunodeficiency Syndrome) Clinical Trials Group Protocol-076; CBC, complete blood count; PCR, polymerase chain reaction; and HIV, human immunodeficiency virus.

  • Test mother or neonate if maternal status for other infections has not been assessed (see text).

  • Zidovudine therapy to decrease the risk of HIV infection in the infant is discontinued at 6 weeks of age.

  • § CBC and differential leukocyte count should continue to be done monthly beyond 4 months of age in the infected child and the child whose infection status is unclear at 4 months.

  • Repeat PCR or viral culture immediately if positive to confirm infection. If initial test is negative, repeat test at 4 weeks to 2 months. If clinical status or other laboratory parameters suggest HIV infection, repeat testing earlier than 4 months. If at 4 months the tests are still negative for infection, ongoing serologic follow-up is indicated.

  • T-cell profile should be repeated at 6 months in infected children and in those whose infection status is unclear at 6 months.

  • # Haemophilus influenzae vaccine schedule may vary depending on which type of vaccine is used.